

COLLABORATION

Creating an effective platform for communication and exchange

KNOWLEDGE

INTERCHANGE

COMMUNICATION

NETWORKING


ADVANCEMENT

The 2013 Annual Report of the Society for Neuro-Oncology

SNO

Society for NeuroOncology

This Annual Report covers the SNO 2013 fiscal year, from July 1st, 2012 through June 30, 2013.



INTERCHANGE

COLLABORATION

COMMUNICATION

EXCHANGE

PERSPECTIVES

A Message from the President



Dear Colleagues and Friends,

As the outgoing President, I am happy to share with you some of the Society's accomplishments and endeavors during my tenure. To begin with, SNO continues to grow with an overall increase in membership of 11% since October 2012, with current membership now approaching 1500 and representation from 42 countries.

I am likewise happy to share that the impact factor of the Society's official journal, *Neuro-Oncology*, continues to rise, now standing at 6.1, solidifying its reputation as the leading journal in the field. Its success is, in large part, due to the dedication of the editor-in-chief, W K Alfred Yung who completes his successful tenure at the end of this year. Dr. Yung has set high-quality standards for the journal which I am certain the new editor-in-chief, Patrick Wen, will continue. I also look forward to the publication of our new journal, *Neuro-Oncology Practice*, which will be edited by Dr. Susan Chang with the support of an editorial board comprised of internationally respected experts from a range of disciplines.

Our Society stands today on the threshold of dramatic new discoveries in the field of neuro-oncology. So that SNO is well positioned to meet the challenges that lie ahead, a group of key SNO members representing a range of disciplines participated in a two-day retreat with a goal of charting a course for next chapter in our organization's evolution. This effort resulted in a forward-looking strategic plan that I believe will be our roadmap to achieving our organizational objectives over the next five years. I am excited that President-elect David Reardon will take the helm to work on these initiatives in an effort to make SNO serve its membership in the best way possible.

I would like to acknowledge some of the individuals who have contributed to the success of our Society and by extension furthered the development of neuro-oncology as a field. First, much appreciation goes to SNO Foundation members Mark Gilbert (chair), Mitchel Berger, Susan Chang and Victor Levin and members of the Partners Advisory Council for their continued support and guidance as the Society continues to grow. I would also like to recognize the members of the Board of Directors for their willingness to represent the diverse disciplines of the neuro-oncology community and for their input into critical aspects of operating the Society.

Thanks go to Jan Esenwein, Linda Greer, Megan Bell and Kristin Odom for their administrative support, and especially to Chas Haynes for his outstanding leadership. This team provides the continuity needed to allow smooth transitions between leadership periods and maintains a cohesive infrastructure for the Society.

As I finish my term, I thank all the members of SNO for your support throughout the past two years. I remain confident that SNO will continue to lead the way and provide a model of cooperation that will ultimately result in improved outcome and quality of life for patients with CNS tumors.

Sincerely,

A handwritten signature in black ink, appearing to read 'Ken Aldape'.

Kenneth Aldape, MD
SNO President



A Message from the Executive Director



Dear Society Members,

It is with great pleasure that I submit this 2013 Annual Report to the members and friends of the Society for Neuro-Oncology. As you read through the pages of this Report, I hope you will agree that much has been accomplished in the last twelve months and that many exciting opportunities lie ahead.

The Society thanks Kenneth Aldape for his thoughtful and steady leadership during his tenure as President. In addition to presiding over a period of unprecedented growth both in terms of membership and attendance at our annual meeting, Dr. Aldape instituted a strategic planning process that is helping to guide the next phase of our organization's evolution. As a result of Dr. Aldape's efforts, our incoming President, David Reardon, takes the reigns of a dynamic organization that is focused on adding value to its members.

We continue to seek out meaningful opportunities for collaboration with other organizations with similar goals. To that end, we partnered with the Section on Tumors on a special meningioma satellite meeting, held jointly organized educational sessions with the American Academy of Neurology at our respective meetings, and organized special SNO sessions at the annual meetings of the Asian Society for Neuro-Oncology and European Association of Neuro-Oncology. We also joined with the Pediatric Brain Tumor Foundation and the National Brain Tumor Society on several important initiatives to advance basic and translational pediatric research.

This year has been an exceptional year for our flagship journal, *Neuro-Oncology*. Under the editorial care of Editor in Chief W K Alfred Yung, the journal remains not only the seminal publication in the field of neuro-oncology, but one of the top ranked oncology titles in the world. The Society is confident that Patrick Wen,

who assumes the leadership of the journal in January of 2014, will continue this positive trajectory and build on Dr. Yung's significant accomplishments.


Looking ahead, the Society is excited to announce a partnership with Oxford University Press to launch a second journal, entitled *Neuro-Oncology Practice*, in the first quarter of 2014. We expect this new publication to become an important resource on clinical best practices and patient care through which readers will learn of the latest developments in clinical decision-making, molecular profiling, advanced imaging, symptom management, quality of life, psychosocial support and a range of other important topics on the applied and practical aspects of neuro-oncology. Edited by Susan Chang, the title will be published initially on a quarterly basis, and will be included as a value added benefit of membership in the Society.

Thanks to the efforts of our volunteer leadership, dedicated members and partner organizations, the Society for Neuro-Oncology stands ready to support the work of those on the frontlines of neuro-oncology clinical care and research. I would like to acknowledge Jan Esenwein, Linda Greer, Megan Bell and Kristin Odom for their tireless efforts on behalf of the Society. In closing, it has been a highly productive and positive year for our Society, and it is therefore with confidence and optimism that we approach the challenges that ahead.

A handwritten signature in black ink, appearing to read "J. Charles Haynes, JD". The signature is fluid and cursive, written in a professional style.

J. Charles Haynes, JD
SNO Executive Director

A Message from the SNO Foundation



Dear Society for Neuro-Oncology Members and Supporters,

On behalf of the SNO Foundation, I am pleased to report on the activities of your Foundation over the past year.

As the fundraising arm of SNO, the Foundation partners with the Society to support educational resources to better assist the clinicians, basic scientists, nurses and other health care professionals whose focus is central nervous system tumors in children and adults.

The support of our corporate and nonprofit partners, as well as the generosity of our members, allows us to maintain the editorial office of *Neuro-Oncology*, the SNO administrative office, SNO's international outreach efforts, as well as the costs associated with the SNO annual meeting, research awards and initiatives for young investigators.

Thanks to your generosity, this year the Foundation was able to make several strategic investments back into the field. These included financial support for:

- A webcast of "SNO Highlights" from the annual meeting
- The Society's first ever town-hall style meeting
- Twelve meeting travel scholarships selected through a competitive application process
- Sponsorship of the abstract supplement for the Pediatric Basic Science Conference
- Improvements in the audio-visual systems for the annual meeting

Most significantly, as you will read further in this Annual Report, our Society is about to embark on a very exciting initiative to publish a companion journal to our

flagship publication, *Neuro-Oncology*. With support of the National Brain Tumor Society, the Foundation is pleased to provide the seed-money needed to launch *Neuro-Oncology Practice*.

To fund the types of efforts like the new journal that will truly have an impact on the future of our field, the Foundation relies on the support of our corporate and foundation partners as well as individual society members. The non-profit associations, foundations and societies, and corporate donors who support the annual meeting at the highest level with a multi-year commitment are members of the Partner's Advisory Council, which has direct access to the SNO Board of Directors and Foundation Executive Board on a regular basis. The 2013 members of the Council include the Genentech, the National Brain Tumor Society, Merck, the Pediatric Brain Tumor Foundation, and the Sontag Foundation. This year we are pleased to welcome Novocure as our newest Advisory Council member.

The SNO Foundation remains committed to supporting important new initiatives and we continue to look ahead for additional opportunities to realize our common mission – finding a cure for brain tumors.

Very truly yours,

Mark R. Gilbert, MD (Foundation President)

Mitchel S. Berger, MD

Susan M. Chang, MD

Victor A. Levin, MD

A Forum for Sharing the Latest Laboratory and Clinical Research

17TH ANNUAL SCIENTIFIC MEETING AND EDUCATION DAY OF THE SOCIETY FOR NEURO-ONCOLOGY

The 17th Annual Scientific Meeting of the Society for Neuro-Oncology was held November 15–18, 2012, in Washington, D.C. SNO thanks E. Antonio Chiocca (Scientific Chair), Balveen Kaur and Vinay Puduvalli (Education Day Co-Chairs), and Michael Glantz (Quality of Life Chair), for composing a comprehensive program highlighting cutting-edge laboratory and clinical research in the field of neuro-oncology. The meeting resulted in a stimulating exchange of ideas among neuro-oncologists, medical oncologists, neurosurgeons, neuropathologists, radiation oncologists, neuroradiologists, pediatricians, laboratory scientists, nurses and other specialists involved in the research, diagnosis, care and treatment of patients with tumors of the central nervous system. In addition to the thought-provoking Education Day and the abstract driven scientific sessions of the main meeting, SNO offered a number of innovative features at the 2012 meeting, including a special biomarkers course, a keynote address from Bert Vogelstein, a new Public Service Award, the inaugural Abhijit Guha Award and Lecture, expanded sessions for Young Investigators, and an evening satellite symposium on 1p/19q codeleted anaplastic gliomas.

Education Day

The meeting began on Thursday, November 15th with an opportune and relevant program for the Education Day consisting of concurrent morning sessions entitled *Targeted Therapies Against Primary Brain Tumors* and *Quality of Life / Symptom Management*. The afternoon session offered a novel program titled SNO Course on the *Basics of Biomarkers*.

SNO Annual Meeting

The formal meeting launched on Friday November 16th with Sunrise Sessions on the following topics: 1) EANO and SNO Joint Session: From Guidelines to New Trials in Low Grade Gliomas: The American and European Views; 2) NF2 Update: Hearing Restoration and Foundations for the Future; 3) Energetics and Metabolism; 4) Re-engineered T Cells and Bone Marrow Cells. The first plenary session began with an official meeting welcome by Dr. Chiocca followed by a Public Service Award presented to Edward Shaw and by presentation of top-Scoring Abstracts.

Subsequent to these events the first Abhijit Guha Award was bestowed to James Rutka, and we heard an invigorating keynote lecture given by Bert Vogelstein.

A Young Investigators Luncheon Roundtable was held at noon on Friday at which trainees and early phase independent investigators participated in informal discussions with senior investigators at roundtables organized into a variety of different areas. Afternoon concurrent sessions included: 1) Medical, Neuro- and Radiation Oncology and 2) Basic Sciences. The next set of concurrent sessions included 1) Symptom Management, Neuro-cognitive and Quality of Life; and 2) Molecular Epidemiology, -Omics and Prognostic Markers. After an exciting, first of its kind, town-hall style meeting on the management of 1p/19q co-deleted anaplastic gliomas, the evening opened for poster sessions, which was an opportunity for lively discussion and debate.

Saturday, November 17th Sunrise Sessions featured the following topics: 1) Asian Society for Neuro-Oncology Session; 2) CMV and Glioma Connection; 3) Mechanisms of Glioblastoma Immuno-evasion; 4) Pituitary Tumors: Biology and Treatment. Next in line was the presentation of the Victor Levin Award and Lecture by Gregory Cairncross and Robert Jenkins. The first afternoon concurrent sessions were 1) Cell Biology/ Signaling and Epidemiology or 2) Pathology and Radiology with subsequent afternoon concurrent sessions on 1) Angiogenesis/Invasion and 2) Surgery and Immunology. The second lively poster session took place after the oral sessions concluded for the day. That evening, the SNO Banquet beheld itself as the social highlight of the meeting.

Sunday, November 18th witnessed the first SNO highlights session—an invitation only press program that highlighted new advances in neuro-oncology, major trial results, and significant advances in supportive care and patient quality of life. Sunrise Sessions included: 1) Oncolytic Viruses: Clinical Trials Update; 2) The Radiobiology of CNS Tumors; 3) The Biology of Brain Metastases; and 4) MicroRNA Biology in CNS Tumors. These were followed by a plenary session presenting Top Scoring Abstracts and a RANO session prior to the meeting adjournment.



Edward Shaw (L) was recognized at the opening of the meeting as the inaugural recipient of the SNO Public Service Award, presented to him by meeting chair E. Antonio Chiocca (R) for his many years of service to the Society and his support of SNO's mission.



Gregory Cairncross (L) and Robert Jenkins (C) received the Levin Award from SNO President Kenneth Aldape (R), and delivered a joint presentation entitled Science, Medicine and Oligodendrogloma.



James Rutka delivered the inaugural Abhibit Guha Award and Lecture entitled Glioblastoma Invasion, Advances from the Leading Edge. SNO was honored to host the Guha family who were present for the lecture. Shown from left to right: Deep Guha, Soma Guha, Tanya Guha, James Rutka, and Frederick Lang.



Bert Vogelstein (L) delivered an invigorating Keynote Address entitled Cancer Genomes and their Implications for Research and Practice, and received a plaque from meeting chair E. Antonio Chiocca (R).

Abstract Award Winners

Sebastian Bender

Award for Excellence in Pediatric Basic Science
Supported by the Pediatric Brain Tumor Foundation
Molecular characterization of mutated histone in pediatric glioblastoma

Justin Lathia

Award for Adult Basic Science
Supported by the National Brain Tumor Society
Know thy enemy: the development of imaging models to interrogate the complexity of cancer stem cells in malignant brain tumors

Olivier Chinot

Award for Adult Clinical Research
Phase III trial of bevacizumab added to standard radiotherapy and temozolomide for newly-diagnosed glioblastoma: mature progression-free survival and preliminary overall survival results in AVAglio

Jonathan L. Finlay

Award for Pediatric Clinical Research
Final Report of Outcome of the CCG-99703 Children's Oncology Group Study for Children Less Than 3 Years of Age Newly-Diagnosed with Malignant Brain Tumors

Rakesh Jalali

Award for Quality of Life
Supported by the Sontag Foundation
Hippocampus as a dose constraint model to preserve neurocognition in young patients with low-grade brain tumors treated with focal stereotactic conformal radiotherapy: data from a prospective clinical trial

Robert B. Jenkins

Award for Excellence in Epidemiology
Supported by EMD Serono
New low frequency risk loci in the 8q24.21 (CCDC26) region are strongly associated with risk of oligodendroglial tumors and IDH1/2 mutated astrocytomas

Ralf S. Schmid

Award for Excellence in Adult Basic Science
Supported by Genentech
Cortical GFAP+ astrocytes as a potential cellular origin of GBM

Shih-Shan Lang

Award for Excellence in Pediatric Translational Science
Supported by the Pediatric Brain Tumor Foundation
Development of pediatric glioma models for BRAF-targeted therapy

Michael Weller

Award for Adult Clinical Research
MGMT promoter methylation predicts benefit from temozolomide versus radiotherapy in malignant astrocytomas in the elderly

Gelareh Zadeh

Award for Excellence in Adult Translational Research
Supported by Merck, Inc.
Spatiotemporal regulation of GBM neo-vascularization and response to therapy

SPOTLIGHT ON THE JOURNAL

Neuro-Oncology

Neuro-Oncology, the official journal of the Society for Neuro-Oncology, experienced yet another year of unprecedented success in its effort to help SNO meet its goal of advancing multidisciplinary research and education in neuro-oncology. It is also approaching significant changes, as Patrick Wen at Dana-Farber Cancer Institute will take on the role of Editor-in-Chief in 2014.

Record High Impact Factor

The editors and staff are thrilled to announce that *Neuro-Oncology's* impact factor for 2012 is 6.180, a record high (Figure 1). Of note, the journal's only direct competitor received a score of 3.115. *Neuro-Oncology* is now ranked 24 of 196 oncology journals and 10 of 192 clinical neurology journals.

Increase in Submitted and Published Articles

The journal experienced a continued increase in the number of new submissions in 2013. The editors—Editor-in-Chief W. K. Alfred Yung, SNO Executive Editor C. David James, JSNO Executive Editor Ryo Nishikawa, and EANO Executive Editor Michael Weller—will have acted on a projected 991 new and revised manuscripts by the end of 2013 (Table 1), an increase over the previous year. From January 1 through September 30, 146 papers were accepted for publication. The journal's acceptance rate is approximately 20%, which demonstrates a continued dedication to publishing only the most significant research, even as the number of submissions increase.

Through the October issue, *Neuro-Oncology* had published 144 articles in 1452 pages (versus 129 in 1313 pages as of October 2012), demonstrating continued growth. The journal also published the abstracts of the International Symposium on Pediatric Neuro-Oncology, the British Neuro-Oncology Society and of course SNO. The journal also published its first supplemental issue, which was edited by Susan Chang and addressed the applied and practical aspects of neuro-oncology.

As of September 30, *Neuro-Oncology* had received manuscripts from 39 countries—38% from the United States and Canada, 36% from Europe, and 21% from Asia. Approximately half of all accepted papers were from the United States and Canada.

Neuro-Oncology appoints new Editor-in-Chief

Patrick Wen has been appointed as the new Editor-in-Chief of the Society's flagship journal, *Neuro-Oncology*. Dr. Wen is Professor of Neurology at Harvard Medical School and Director of the Center for Neuro-Oncology at




Patrick Wen (L) will seek to build on the impressive legacy of W. K. Alfred Yung (R) who guided the journal to new heights during his successful tenure as Editor-in Chief.

Dana-Farber/Brigham and Women's Cancer Center in Boston, Massachusetts. He was formerly Vice President of SNO and is currently Chair of the Neuro-oncology Section of the American Academy of Neurology. His research focuses on novel therapeutics for brain tumours and optimizing response assessment and trial designs.

Dr. Wen takes the reins of a publication that has gone from strength to strength under the leadership of W. K. Alfred Yung who was appointed Editor-in-Chief of *Neuro-Oncology* in 2007. During Dr. Yung's tenure, the journal increased in frequency from four to six issues per year, and then again to twelve issues per year. In addition, Dr. Yung guided the journal's Impact Factor to an impressive 6.180, which puts *Neuro-Oncology* among the world's top oncology and neurology titles.

Professor Wen looks forward to working with the European Association of Neuro-Oncology (EANO), and the Japanese Society for *Neuro-Oncology* (JSNO) to build on the wonderful legacy of Dr. Yung, in making *Neuro-Oncology* the foremost journal in the field and advancing our mission of developing better treatments and improving the quality of life of brain tumour patients and patients with neurologic complications of cancer.



Type of manuscript	2010	2011	2012	2013 through Sept. 30, 2013 (projected end of year)
New	411	454	669	527 (704)
Revised	153	217	244	215 (287)
Total	564	671	913	742 (991)

Table 1. Number of new and revised manuscripts submitted

Figure 1. *Neuro-Oncology's* impact factors. The impact factor, published annually by Thomson Scientific in the Journal Citation Reports, is determined using article citation rates and is used to measure journal quality.

Peer & Statistical Reviewers

Neuro-Oncology is indebted to the members of its editorial board (whose names appear in every issue of the journal) and its numerous peer and statistical reviewers, all of whom have helped the journal along its path to success. Listed below are those reviewers who had conducted manuscript reviews as of September 30. The staff apologizes for any inadvertent omissions.

Roger Abounader
 Manish Aghi
 Atique Ahmed
 Ovidiu Andronesi
 James Michael Angelastro
 Terri S. Armstrong
 Carles Arus
 Dusica Babovic-Vuksanovic
 Krystof Bankiewicz
 Jill S. Barnholtz-Sloan
 Ute Bartels
 Oren Becher
 Elizabeth Beierle
 Etty Benveniste
 Stefan Blüml
 Oliver Bogler
 John Boockvar
 Eric Bouffet
 Michael Brada
 Alba Ariela Brandes
 Priscilla Brastianos
 William Broaddus
 Alberto Broniscer
 Nicholas Butowski
 J. Gregory Cairncross
 Kevin Camphausen
 Carmine M. Carapella
 Robert Craig Castellino
 Sharon Castellino
 Alain Charest
 Clark Chen
 Pin-Yuan Chen
 Prakash Chinnaiyan
 Yoon-Jae Cho
 Chun Kee Chung
 Jennifer Clarke
 Timothy F. Cloughesy
 Kenneth J. Cohen
 Rivka Colen
 Howard Colman
 Denise D. Correa
 Sidney Croul
 Faith G. Davis
 John de Groot
 Waldemar Debinski
 Steven De Vleeschouwer

Harshil Dhruv
 Adam P. Dicker
 Linda Douw
 Francois Doz
 Janet Eary
 Charles Eberhart
 Anat Erdreich-Epstein
 Bradley J. Erickson
 Jason Fangusaro
 Christian T. Farrar
 Andres Ferreri
 Elisabetta Ferretti
 Isaiah J. Fidler
 Graziella Filippini
 Paul B. Fisher
 Paul Graham Fisher
 Tullio Florio
 Peter A. Forsyth
 Karl Frei
 Juan Fueyo-Margareto
 Takamitsu Fujimaki
 Mitsugu Fujita
 Robert Fulbright
 Karin Gehring
 Felice Giangaspero
 Mark R. Gilbert
 Maria Teresa Giordana
 Candace L. Gladson
 Roseline Godbout
 Candelaria Gomez-Manzano
 Corinne Griguer
 Nalin Gupta
 Daphne A. Haas-Kogan
 Chunhai (Charlie) Hao
 Elke Hattingen
 Cynthia Hawkins
 James E. Herndon, II, Ph.D.
 Christel Claudia Herold-Mende
 Ulrich Herrlinger
 Kenneth Robert Hess, PhD
 Khê Hoang-Xuan
 Craig Horbinski
 Jason T. Huse
 Ahmed Idbaih
 Yasushi Ino

Peter D. Inskip
 Alexander Iomin
 Mark A. Israel
 Fabio M. Iwamoto
 Nada Jabado
 Rakesh Jalali
 Derek Johnson
 Annette Johnson
 Thomas Kaley
 Bozena Kaminska
 Seok-Gu Kang
 Yukinari Kato
 Santosh Kesari
 Raja B. Khan
 Soumen Khatua
 Elmar Kirches
 Gaspar Kitange
 Lan Kluwe
 Tomasz Kordula
 Peter Krauseneck
 Steven Kridel
 Anand S. Lagoo
 Tamara Lah
 Albert Lai
 Katrin Lamszus
 Joseph C. Landolfi
 Andrew B. Lassman
 Justin Lathia
 Sean Edward Lawler
 Florence Lefranc
 Maciej Lesniak
 Jing Li
 David N. Louis
 Robert A. Lustig
 Lorenzo Magrassi
 Peter Manley
 Juan Pedro Martinez-Barbera
 Warren Mason
 Maura Massimino
 Akira Matsuno
 Alex McMillan
 Thomas E. Merchant
 C. Ryan Miller
 Duane A Mitchell
 Shin-Ichi Miyatake
 Annette Molinaro

Sabine Mueller
 Akitake Mukasa
 Satoshi Nakasu
 Yoko Nakasu
 Sarah Nelson
 Edward A Neuwelt
 Simone P. Niclou
 Theodore Nicolaides
 Andrew Norden
 Brian P. O'Neill
 Hideho Okada
 Antonio Omuro
 Ashok Panigrahy
 Ilwoo Park
 Deric M. Park
 John Park
 Ian Parney
 Marta Penas-Prado
 Giorgio Perilongo
 Anders Persson
 Claudia Petritsch
 Stefan Pfister
 Joanna Phillips
 David Piccioni
 Michael Platten
 Ian F. Pollack
 Scott L. Pomeroy
 Whitney Pope
 Hans S. Poulsen
 Sujit Prabhu
 Nikolai Rainov
 Jeffrey J. Raizer
 Preetha Rajaraman
 Zvi Ram
 Jaap C. Reijneveld
 Sabrina Ronen
 Ally Rooney
 Lucy B. Rorke-Adams
 Steven S. Rosenfeld
 Mark A Rosenthal
 James Rubenstein
 Joshua B Rubin
 Stefan Rutkowski
 Ettore Salsano
 Stephen A. Sands
 Raymond Sawaya

Adrienne C. Scheck
 Dawid Schellingerhout
 Kathleen M. Schmainda
 S. Clifford Schold
 Judith Schwartzbaum
 Thomas N. Seyfried
 Wenyin Shi
 Soichiro Shibui
 Mitsuaki Shirahata
 Tali Siegal
 Ralph Sinkus
 Andrew Edward Sloan
 Robert W. Sobol
 Kumaravel Somasundaram
 Verena Staedtke
 Kazuhiko Sugiyama
 Erik Sulman
 Ghazaleh Tabatabai
 Sophie Taillibert
 Hideo Takeshima
 Marumoto Tomotoshi
 Miguel Torres-Martin
 Rheel Towner
 Gail E. Tudor
 Keisuke Ueki
 Luis Vence
 Andreas Waha
 David A. Walker
 Kyle Walsh
 Jun Wang
 Monika Warmuth-Metz
 Katherine Warren
 Samuel Weiss
 Elizabeth M. Wells
 Shun Wong
 Thomas Wurdinger
 Bakhtiar Yamini
 Hai Yan
 Stephen Yip
 Seiichi Yoshida
 David Zagzag
 Wei Zhang
 Xiang Zhang

ADVANCING PROFESSIONAL EXCHANGE

As part of our ongoing effort to better understand CNS malignancies and bring new perspectives to the field, SNO strives to reach out and collaborate with sister groups that share our scientific mission. Highlights of these interorganizational efforts are described below.

Pediatric Neuro-Oncology Basic and Translational Research Conference

The 2nd Biennial Pediatric Neuro-Oncology Basic and Translational Research Conference took place in Fort Lauderdale on May 16-17, 2013, at the Hyatt Pier 66 Hotel. The meeting was supported with a grant from the Pediatric Brain Tumor Foundation (PBTf), and organized by the Society for Neuro-Oncology. SNO and PBTf thank James Rutka for serving as the scientific chair this very successful event.

More than 270 clinicians, scientists, research students, and post-doctoral fellows participated in the conference. There was representation from more than 15 countries with some of the more distant sites of origin being China, Australia, and Japan.

Over a packed two day period, attendees learned of the latest developments in pediatric basic science and translational therapeutics, covering medulloblastoma, ependymoma, high grade glioma and diffuse intrinsic pontine glioma. Plans are already underway for the next conference devoted therapeutic strategies to benefit children with these aggressive cancers. Abstracts of the original research submitted to the conference were published in the Society's journal, *Neuro-Oncology*.

Multidisciplinary Management of Meningioma Symposium



SNO partnered with the Section on Tumors (SOT) of the AANS/CNS to collaboratively develop a one-day symposium dedicated to the multidisciplinary management of meningiomas. The symposium, which was held on April 27, 2013, in New Orleans, was developed by Patrick Wen (SNO), Leland Rogers (SNO) and Michael Vogelbaum (SNO and

SOT). The symposium covered all aspects of meningioma including recent advances in pathology, imaging, biology, treatment options, and clinical investigation.

Highlights of the invited speaker program included discussions of recent advances in understanding the genetics and grading of meningiomas, a review of new murine models for studying the pathobiology of meningiomas, an insightful evaluation of the longterm risk of recurrence and its relation to extent of resection, discussions of radiation therapy and radiosurgery and discussions of new investigational therapies. In addition, there were oral presentations of original science competitively selected from abstract submissions addressing a wide range of topics, including new genes associated with the development of meningiomas, mTOR inhibitors, a novel immunotherapy, development of murine models and novel imaging methods for discriminating between grades of meningioma.

19th Annual Neuro-Tumor Club Dinner Meeting

The 19th Annual Neuro-Tumor Club Dinner Meeting took place on April 8, 2013, at the Washington Plaza Hotel in Washington, DC. This meeting, for brain tumor researchers attending the annual meeting of the American Association of Cancer Researchers (AACR), was organized by the Society for Neuro-Oncology with the support of Genentech, Merck and the National Brain Tumor Society. The event drew approximately 200 investigators from diverse disciplines relevant to brain tumor research, and was very successful in strengthening existing personal research connections and collaborations, generating new associations and presenting the group with updates in topics important to brain tumor research.

The talks, selected through a competitive application process, were arranged in four consecutive sessions encompassing a range of important topic areas including animal models, biomarkers, stem cells, CNS metastases, personalized combinatorial therapy and immunotherapy. SNO thanks John Park and Raymund Yong for chairing this stimulating and thought-provoking meeting.

SNO TO PUBLISH NEW JOURNAL

Oxford University Press and SNO are pleased to announce that they will be publishing a new journal, *Neuro-Oncology Practice*, beginning in 2014. The new journal will be edited Dr. Susan Chang, Director of the Division of Neuro-Oncology at UCSF, in San Francisco, California, USA.

The field of neuro-oncology focuses on the research and treatment of brain and spinal tumours. *Neuro-Oncology Practice* will cover applied neuro-oncology, filling a need for practical and educational content. This new journal will also provide the multidisciplinary field of neuro-oncology professionals, such as physicians, nurses, physical and occupational therapists, palliative care specialists, and neuropsychologists, with clinical information to enhance patient care, quality of life, psycho-social support, and management of co-morbid conditions.




**National
Brain Tumor
Society**

The launch of this new title was made possible by a generous grant from the National Brain Tumor Society.

Some of the aims of *Neuro-Oncology Practice* include:

- To apply new trial results to improve standards of patient care,
- To translate scientific advances, such as tumour molecular profiling and advanced imaging, into clinical treatment decision-making and personalized brain tumour therapies, and
- To raise awareness of basic, translational, and clinical research in areas of symptom management, survivorship, neurocognitive function, end of life issues, and caregiving.

Neuro-Oncology Practice will be the sister journal to *Neuro-Oncology*, SNO's official journal, which Oxford has published since 2010.



The editorial structure of *Neuro-Oncology Practice* will mirror that of *Neuro-Oncology*, with representation from SNO's sister societies in Europe and Asia.



Susan Chang
Editor-in-Chief

Rakesh Jalali
ASNO Editor

Wolfgang Grisold
EANO Editor

Jeffrey Wefel
SNO Editor

Susan Chang will serve as the Editor-in-Chief of the new title that SNO will be publishing with Oxford University Press.

Society For Neuro-Oncology

Financial Highlights

Fiscal Year Ended June 30, 2012

The following financial highlights are prepared by management of Society for NeuroOncology for the fiscal year ended June 30, 2012 and are intended for this Annual Report, only. The financial information is in the process of being audited by an independent accounting firm. Once the audit is complete, the financial statements and Independent Auditor's Report will be posted at www.soc-neuro-onc.org.

Statement of Financial Position highlights, as of June 30, 2012

Cash and cash equivalents	\$ 1,240,000
Investments	564,000
Contributions receivable	48,000
Endowment assets	156,000
Total assets	\$ 2,008,000
Liabilities	\$ 257,000
Net assets	1,751,000
Total liabilities and net assets	\$ 2,008,000

Statement of Activities highlights, for the fiscal year ended June 30, 2012

Total revenues and other support	\$ 1,821,000
Total program and supporting service expenses	1,385,000
Change in net assets	\$ 436,000

Society For Neuro-Oncology

Financial Highlights

Fiscal Year Ended June 30, 2013

The following financial highlights are prepared by management of Society for NeuroOncology for the fiscal year ended June 30, 2013 and are intended for this Annual Report, only. The financial information is in the process of being audited by an independent accounting firm. Once the audit is complete, the financial statements and Independent Auditor's Report will be posted at www.soc-neuro-onc.org.

Statement of Financial Position highlights, as of June 30, 2013

Cash and cash equivalents	\$ 1,400,000
Investments	676,000
Contributions receivable	25,000
Endowment assets	178,000
Other assets	65,000
Total assets	\$ 2,365,000
<hr/> <hr/>	
Liabilities	\$ 229,000
Net assets	2,136,000
Total liabilities and net assets	\$ 2,365,000
<hr/> <hr/>	

Statement of Activities highlights, for the fiscal year ended June 30, 2013

Total revenues and other support	\$ 2,103,000
Total program and supporting service expenses	1,888,000
Change in net assets	\$ 215,000
<hr/> <hr/>	

ADMINISTRATIVE STAFF



Executive Director

J. Charles (Chas) Haynes, J.D.

Chief Administrative Officer

Jan Esenwein

Membership Manager

Linda Greer

Administrative Coordinator

Megan Bell

Communications Coordinator

Kristin Odom

Society for Neuro-Oncology

4617 Birch Street
Bellaire TX 77401
tel 713.349.0952
fax 832.201.8129

www.soc-neuro-onc.org

OFFICERS, BOARD OF DIRECTORS AND COMMITTEES

President

Kenneth Aldape, MD

Vice President

Michael Vogelbaum, MD, PhD

Secretary-Treasurer

E. Antonio Chiocca, MD, PhD

Board of Directors

Eric Bouffet, MD

Sherry Fox, PhD

Mary Lovely, PhD

Andrew Parsa, MD

David Peereboom, MD

Russell Pieper, PhD

David Reardon, MD

Jann Sarkaria, MD

Michael Taylor, MD, PhD

Past President

Frederick Lang, MD

Foundation Board

Mark R. Gilbert, MD (President)

Victor A. Levin, MD (SNO Founder)

Mitchel S. Berger, MD

Susan Chang, MD

Journal Editor in Chief

W. K. Alfred Yung, MD

Journal Executive Editor (SNO)

C. David James, PhD

SNO STANDING COMMITTEES

The Audit Committee shall consist of the Chair, Vice President of the Society and the Secretary-Treasurer. The committee shall have the responsibility of overseeing annual internal audit of the Society's financial affairs, and conveying the audit to the President and the Board, who may approve review of the audit by external committees as needed. The committee shall also advise and make recommendations to the Board of Directors based on findings of such audits. The Audit Committee members shall serve a two-year term and such term may be renewable at the discretion of the President.

Chair: Gene Barnett

The Awards Committee shall consist of the Chair, the Scientific Program Chair and other members who shall develop criteria for all SNO meeting awards, annually review meeting award candidates, and forward to the Board a list of awards and award recipients to be honored at the Annual Meeting. The Awards Committee members shall serve a two-year term and such term may be renewable at the discretion of the President.

Chair: David Eisenstat

The Bylaws Committee shall consist of the Chair, the Secretary/Treasurer (ex officio) and two other members who shall review the Bylaws annually and make recommendations for revision as necessary. Members of this committee shall review any proposed changes and advise the Board of Directors on proposed revisions. The Bylaws Committee members shall serve a two-year term and such term may be renewable at the discretion of the President.

Chair: Thomas Mikkelsen

The Communications Committee shall consist of the Chair, the Secretary/Treasurer (ex officio) and other members who shall be responsible for the news section of the Society's official journal and the Society's newsletter, and will have the responsibility of advising the Board of Directors on the Society's internal and external communications. The Communications Committee members shall serve a two-year term and such term may be renewable at the discretion of the President.

Chair: Nicholas Butowski

The Future Sites Committee shall consist of the Chair, a previous Chair of the Annual Meeting Committee and two other members who shall review potential sites and hotel proposals for future meetings, evaluating size and appropriateness of meeting space, availability and quality of sleeping rooms, proposed room rates, and recommends to the Board the most appropriate venue. The Future Sites Committee members shall serve a two-year term and such term may be renewable at the discretion of the President.

Co-Chairs: Jonathan Knisely and Mark Gilbert

The International Outreach Committee shall consist of the Chair and other representative international members recommended by the Chair or President, as approved by the Board of Directors. The committee shall have the responsibility of advising and making recommendations to the Board of Directors on international affairs, promoting international membership, and shall develop the criteria and review candidates for SNO international outreach travel grants and fellowships. The International Outreach Committee members shall serve a two-year term and such term may be renewable at the discretion of the President.

Chair: Eric Bouffet

The Annual Meeting Committee shall consist of a Scientific Program Chair, Education Day Chair, the immediate past Chairs of the Annual Meeting Committee and other members representing each of the SNO specialty areas who shall supervise and coordinate all aspects of the next SNO Scientific Meeting and Education Day. The Meeting Committee members shall serve a one-year term and such term may be renewable at the discretion of the President.

Chair: Antonio Chiocca

The Membership Committee shall consist of the Chair and four members who shall make recommendations to the Board of Directors concerning efforts to promote and increase membership in Society. They shall also review and vote on all applicants for membership and shall evaluate a member's professional conduct as requested by a majority of the Board of Directors. The Membership Committee members shall serve a two-year term and such term may be renewable at the discretion of the President.

Chair: Manmeet Ahluwalia

The Website Committee shall consist of the Chair and other members who shall have the responsibility of coordinating and overseeing the Society's official website. The Website Committee members shall serve a two-year term and such term may be renewable at the discretion of the President.

Chair: Erik Sulman

The Young Investigators Committee shall consist of the Chair and other members who shall have the responsibility of advising the Board of Directors on issues pertaining to graduate students, residents, fellows and members within the first five years of their initial clinical or academic appointment. The Young Investigators Committee shall also have the responsibility of coordinating the SNO Grant Review initiative. The Young Investigators Committee members shall serve a two-year term and such term may be renewable at the discretion of the President.

Chair: Jason Huse

SNO SUPPORTERS

Through 2013 Fiscal Year Ending June 31, 2013

Platinum Level

Genentech
Merck
Novocure
National Brain Tumor Society
Pediatric Brain Tumor Foundation
Sontag Foundation

Benefactors

CERN Foundation

Supporters

American Brain Tumor Association
Brain Tumour Foundation of Canada
Celldex Therapeutics
Chris Elliott Foundation
Northwest Biotherapeutics

International Outreach & Guha Fund

Children's Brain Tumor Foundation
Ali Choucair
Takamitsu Fujimaki
Sontag Foundation
Victor Levin Founders Society

Individual Donations and Levin Society

Wallace Gleason & Family
in memory of Maryjo Gleason
Carol S Gold
Victor and Ellen Levin
Claudia Schlimper
Michael Young
*in memory of William Priestman
Thorpe IV*

Neuro-Tumor Club Meeting

Genentech
Merck
National Brain Tumor Society

Exhibitors

American Brain Tumor Association
Arbor Pharmaceuticals
Castle Bioscience
Celldex
Central Nervous System Tumor
Education Foundation
CERN Foundation
Chris Elliott Foundation and
Musella Foundation
Del Mar
EANO
Elekta
Foundation Medicine, Inc.
Genentech
International Brain Tumour
Association
IsoRay Medical
LabCorp
Leica Microsystems
Magforce AG
Medical Advocates
Monteris Medical
National Brain Tumor Society
Nicki Leach Foundation
Northwest Biotherapeutics, Inc.
Novocure
Oxford University Press
Pediatric Brain Tumor Foundation
Sigma Tau
Tocagen

SNO mourns the loss of the following members:

Gregory Foltz
John Ohlfest


Mission

SNO fosters multidisciplinary neuro-oncology research and education to improve patient outcomes.

Vision

SNO is the pre-eminent multidisciplinary society involved in state-of-the-art neuro-oncology research, education, and patient care.

SNO Members



Society for Neuro-Oncology

4617 Birch Street
Bellaire TX 77401
tel 713.349.0952
fax 832.201.8129

www.soc-neuro-onc.org

